FCA
CALT

FinTrust Capital Advisors’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

FinTrust Capital Advisors’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-450
Closed -$11 – 1168
2020
Q3 		$11 Buy
+450
New +$10.5K ﹤0.01% 791

Other funds holding CALT

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

FinTrust Capital Advisors's CALT Position: Q4 2020 in Review

FinTrust Capital Advisors sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q4 2020, closing a stake of 450 shares — an estimated $11 sold.

FinTrust Capital Advisors first reported a position in CALT in Q3 2020 and held it in 1 quarter. The position peaked at $11 in Q3 2020. 11 funds tracked by Wall St. Rank hold CALT as of Q4 2020.

  • FinTrust Capital Advisors reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q4 2020 after selling out during the quarter.
  • FinTrust Capital Advisors sold 450 Calliditas Therapeutics AB American Depositary Shares shares in Q4 2020, an estimated $11.
  • FinTrust Capital Advisors first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q3 2020 and held it in 1 quarter.
  • FinTrust Capital Advisors's Calliditas Therapeutics AB American Depositary Shares position peaked at $11 in Q3 2020.
  • 11 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q4 2020.

Based on FinTrust Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.